Menu

Three More Coauthors Removed from Macchiarini Paper

Colleagues of the surgeon under investigation distance themselves from a 2011 The Lancet study.

Apr 1, 2016
Kerry Grens

PIXABAY, PUBLICDOMAINPICTURESFollowing the example of Karl-Henrik Grinnemo, a surgeon at the Karolinska Institute, three more coauthors on a 2011 paper in The Lancet have asked to have their names removed from the publication. The senior author of the study, Paolo Macchiarini, has been accused of misconduct, fired from his job at the Karolinska institute, and is the subject of investigations into his work.

The three coauthors “no longer wish to be associated with this paper and ask for their names to be removed,” according to a March 31 correction notice. Twenty-three coauthors remain on the publication.                                                   

Macchiarini has been accused of breaching ethical standards relating to his work on artificial tracheas. The Royal Swedish Academy of Sciences flagged the 2011 study as concerning.

Update (April 1): The Lancet editors have now issued an expression of concern regarding the 2011 paper, Retraction Watch reported. "In view of the ongoing uncertainty about the integrity of the work reported in this paper, and after discussion with the lead author of the research artricle, Dr Paolo Macchiarini, we now issue an expression of concern about the paper, while reserving a final decision for when current investigations are completed," the editors wrote in the notice.

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!